Recent Finacing
Recent Raise
DiObex develops metabolic disease therapies, advancing DIO‑901 VLD glucagon for type 1 hypoglycemia (infusion‑pump and ER formulations) and DIO‑902 cortisol‑synthesis inhibitor for type 2 diabetes.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
